Trial Profile
Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 16 Dec 2022
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Efavirenz; Emtricitabine; Lamivudine; Tenofovir
- Indications HIV infections; HIV-1 infections
- Focus Pharmacokinetics
- Acronyms DOLPHIN-1
- 26 Oct 2022 Data of adverse birth outcomes from 5 studies DolPHIN-1, DolPHIN-2, ADVANCE, NAMSAL and IMPAACT-2010 were presented at the 16th International Congress on Drug Therapy and HIV Infection.
- 12 Dec 2020 Results published in the Clinical Infectious Diseases
- 10 Jul 2020 Results (N=1074), a meta-analysis of 5 clinical trials in pregnant women comparing the efficacy of dolutegravir versus efavirenz for faster virological suppression in pregnancy in the risk of HIV mother-to-child-transmission, presented at the 23rd International AIDS Conference